Header

UZH-Logo

Maintenance Infos

Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives


Hohla, Florian; Winder, Thomas; Greil, Richard; Rick, Ferenc G; Block, Norman L; Schally, Andrew V (2014). Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. World Journal of Gastroenterology, 20(20):6102-6112.

Abstract

The introduction of new cytotoxic substances as well as agents that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling has improved clinical outcome of patients with metastatic colorectal cancer (mCRC). In this review we summarize the most relevant clinical data on VEGF and EGFR targeting regimens in mCRC. The effects of available treatment strategies for mCRC are often temporary, with resistance and disease progression developing in most patients. Thus, new treatment strategies are urgently needed. Some GI peptides including gastrin and gastrin releasing peptide, certain growth factors such as insulin-like growth factor-I and II and neuropeptides such as growth hormone releasing hormone (GHRH) are implicated in the growth of CRC. Experimental investigations in CRC with antagonistic analogs of bombesin/gastrin-releasing peptide, GHRH, and with cytotoxic peptides that can be targeted to peptide receptors on tumors, are summarized in the second part of the review.

Abstract

The introduction of new cytotoxic substances as well as agents that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling has improved clinical outcome of patients with metastatic colorectal cancer (mCRC). In this review we summarize the most relevant clinical data on VEGF and EGFR targeting regimens in mCRC. The effects of available treatment strategies for mCRC are often temporary, with resistance and disease progression developing in most patients. Thus, new treatment strategies are urgently needed. Some GI peptides including gastrin and gastrin releasing peptide, certain growth factors such as insulin-like growth factor-I and II and neuropeptides such as growth hormone releasing hormone (GHRH) are implicated in the growth of CRC. Experimental investigations in CRC with antagonistic analogs of bombesin/gastrin-releasing peptide, GHRH, and with cytotoxic peptides that can be targeted to peptide receptors on tumors, are summarized in the second part of the review.

Statistics

Citations

21 citations in Web of Science®
24 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

15 downloads since deposited on 19 Feb 2015
10 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:Colorectal cancer, Targeted treatment, Vascular endothelial growth factor, Epidermal growth factor receptor, Peptide receptors, Gastrin-releasing peptide, Growth hormone releasing hormone, Luteinizing hormone-releasing hormone, Cytotoxic analogs
Language:English
Date:28 May 2014
Deposited On:19 Feb 2015 15:52
Last Modified:21 Nov 2017 17:45
Publisher:Baishideng Publishing Group Co. Limited
ISSN:1007-9327
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.3748/wjg.v20.i20.6102
PubMed ID:24876732

Download

Download PDF  'Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives'.
Preview
Content: Published Version
Filetype: PDF
Size: 804kB
View at publisher